Epoetin alfa biosimilar (Nanogen)

阿法依伯汀生物类似药 (Nanogen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEpoetin alfa biosimilar (Nanogen)
Drug Alias NameRecombinant human erythropoietin alfa (Nanogen)阿法依伯汀生物仿制药 (Nanogen)Nanokine
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryVietnam
Original Approved Date2014/01/01
Country/TerritoryVietnam
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNanogen Biopharmaceutical Co
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A